Trials / Recruiting
RecruitingNCT07112222
A Study of LM-350 in Subjects With Advanced Solid Tumours
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- LaNova Medicines Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LM-350 for injection | Q3W,Intravenous Drip |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2028-06-30
- Completion
- 2030-06-30
- First posted
- 2025-08-08
- Last updated
- 2026-01-26
Locations
4 sites across 2 countries: Australia, China
Source: ClinicalTrials.gov record NCT07112222. Inclusion in this directory is not an endorsement.